;PMID: 9853427
;source_file_1381.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:45..171] = [t:45..171]
;2)section:[e:175..299] = [t:175..299]
;3)section:[e:303..374] = [t:303..374]
;4)sentence:[e:378..514] = [t:378..514]
;5)sentence:[e:515..599] = [t:515..599]
;6)sentence:[e:600..704] = [t:600..704]
;7)sentence:[e:705..875] = [t:705..875]
;8)sentence:[e:876..963] = [t:876..963]
;9)sentence:[e:964..1049] = [t:964..1049]
;10)sentence:[e:1050..1126] = [t:1050..1126]
;11)sentence:[e:1127..1387] = [t:1127..1387]
;12)sentence:[e:1388..1549] = [t:1388..1549]
;13)section:[e:1553..1597] = [t:1553..1597]

;section 0 Span:0..40
;Cell Prolif  1998 Jun-Aug;31(3-4):139-53
(SEC
  (FRAG (DT:[0..4] Cell) (NNP:[5..11] Prolif) (CD:[13..17] 1998)
        (NNP:[18..21] Jun) (HYPH:[21..22] -) (JJ:[22..30] Aug;31-LRB-3)
        (HYPH:[30..31] -) (JJ:[31..33] 4-RRB-) (CD:[33..37] :139)
        (HYPH:[37..38] -) (CD:[38..40] 53)))

;sentence 1 Span:45..171
;Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras
; point mutations in colorectal liver metastases.
;[108..111]:gene-rna:"p53"
;[116..122]:gene-rna:"Ki-ras"
;[124..139]:variation-type:"point mutations"
;[143..170]:malignancy:"colorectal liver metastases"
(SENT
  (NP-HLN
    (NP (JJ:[45..55] Prognostic) (NN:[56..68] significance))
    (PP (IN:[69..71] of)
      (NP
        (NP (JJ:[72..85] proliferative) (NN:[86..94] activity))
        (,:[94..95] ,)
        (NP (NN:[96..99] DNA) (HYPH:[99..100] -) (NN:[100..106] ploidy))
        (,:[106..107] ,)
        (NP (NN:[108..111] p53))
        (CC:[112..115] and)
        (NP (NN:[116..122] Ki-ras)
           (NN:[124..129] point) (NNS:[130..139] mutations))))
    (PP (IN:[140..142] in)
      (NP (JJ:[143..153] colorectal) (NN:[154..159] liver)
          (NNS:[160..170] metastases)))
    (.:[170..171] .)))

;section 2 Span:175..299
;Russo A, Migliavacca M, Bazan V, Maturi N, Morello V, Dardanoni G, Modica G, 
;Bazan P, Albanese I, La Farina M, Tomasino RM.
(SEC
  (FRAG (NNP:[175..180] Russo) (NNP:[181..182] A) (,:[182..183] ,)
        (NNP:[184..195] Migliavacca) (NNP:[196..198] M,) (NNP:[199..204] Bazan)
        (NNP:[205..206] V) (,:[206..207] ,) (NNP:[208..214] Maturi)
        (NNP:[215..216] N) (,:[216..217] ,) (NNP:[218..225] Morello)
        (NNP:[226..227] V) (,:[227..228] ,) (NNP:[229..238] Dardanoni)
        (NNP:[239..240] G) (,:[240..241] ,) (NNP:[242..248] Modica)
        (NNP:[249..250] G) (,:[250..251] ,) (NNP:[253..258] Bazan)
        (NNP:[259..260] P) (,:[260..261] ,) (NNP:[262..270] Albanese)
        (NNP:[271..272] I) (,:[272..273] ,) (NNP:[274..276] La)
        (NNP:[277..283] Farina) (NNP:[284..286] M,) (NNP:[287..295] Tomasino)
        (NNP:[296..298] RM) (.:[298..299] .)))

;section 3 Span:303..374
;Department of Clinical Oncology Research, University of Palermo, Italy.
(SEC
  (FRAG (NNP:[303..313] Department) (IN:[314..316] of) (NNP:[317..325] Clinical)
        (NNP:[326..334] Oncology) (NNP:[335..343] Research) (,:[343..344] ,)
        (NNP:[345..355] University) (IN:[356..358] of) (NNP:[359..366] Palermo)
        (,:[366..367] ,) (NNP:[368..373] Italy) (.:[373..374] .)))

;sentence 4 Span:378..514
;Paired colorectal liver metastases (CLM) and normal tissue samples from a 
;consecutive series of 36 patients were studied prospectively.
;[385..412]:malignancy:"colorectal liver metastases"
;[414..417]:malignancy:"CLM"
(SENT
  (S
    (NP-SBJ-1
      (NP (VBN:[378..384] Paired)
        (NML
          (NML
            (NML (JJ:[385..395] colorectal) (NN:[396..401] liver)
                 (NNS:[402..412] metastases))
            (NML (-LRB-:[413..414] -LRB-) (NN:[414..417] CLM)
                 (-RRB-:[417..418] -RRB-)))
          (CC:[419..422] and)
          (NML (JJ:[423..429] normal) (NN:[430..436] tissue)
               (NNS:[437..444] samples))))
      (PP (IN:[445..449] from)
        (NP
          (NP (DT:[450..451] a) (JJ:[453..464] consecutive)
              (NN:[465..471] series))
          (PP (IN:[472..474] of)
            (NP (CD:[475..477] 36) (NNS:[478..486] patients))))))
    (VP (VBD:[487..491] were)
      (VP (VBN:[492..499] studied)
        (NP-1 (-NONE-:[499..499] *))
        (ADVP (RB:[500..513] prospectively))))
    (.:[513..514] .)))

;sentence 5 Span:515..599
;MIB-1 expression  was studied by immunohistochemistry on paraffin-embedded
;sections.
;[515..520]:gene-protein:"MIB-1"
(SENT
  (S
    (NP-SBJ-1 (NN:[515..520] MIB-1) (NN:[521..531] expression))
    (VP (VBD:[533..536] was)
      (VP (VBN:[537..544] studied)
        (NP-1 (-NONE-:[544..544] *))
        (PP-MNR (IN:[545..547] by)
          (NP
            (NP (NN:[548..568] immunohistochemistry))
            (PP (IN:[569..571] on)
              (NP
                (ADJP (NN:[572..580] paraffin) (HYPH:[580..581] -)
                      (VBN:[581..589] embedded))
                (NNS:[590..598] sections)))))))
    (.:[598..599] .)))

;sentence 6 Span:600..704
;DNA ploidy  and S-phase fraction (SPF) measurements were performed by flow
;cytometry on  frozen tissues.
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NML (NN:[600..603] DNA) (NN:[604..610] ploidy))
        (NML-1 (-NONE-:[610..610] *P*)))
      (CC:[612..615] and)
      (NP
        (NML
          (NML (NN:[616..623] S-phase) (NN:[624..632] fraction))
          (NML (-LRB-:[633..634] -LRB-) (NN:[634..637] SPF)
               (-RRB-:[637..638] -RRB-)))
        (NML-1 (NNS:[639..651] measurements))))
    (VP (VBD:[652..656] were)
      (VP (VBN:[657..666] performed)
        (NP-2 (-NONE-:[666..666] *))
        (PP-MNR (IN:[667..669] by)
          (NP (NN:[670..674] flow) (NN:[675..684] cytometry)))
        (PP (IN:[685..687] on)
          (NP (VBN:[689..695] frozen) (NNS:[696..703] tissues)))))
    (.:[703..704] .)))

;sentence 7 Span:705..875
;Mutations within the p53 (exons 5-8) and c-Ki-ras (codons 12 and  13) genes
;were detected by PCR single-strand conformation polymorphism analysis 
;followed by sequencing.
;[705..714]:variation-event:"Mutations"
;[726..729]:gene-rna:"p53"
;[731..740]:variation-location:"exons 5-8"
;[746..754]:gene-rna:"c-Ki-ras"
;[756..765]:variation-location:"codons 12"
;[756..762]...[771..773]:variation-location:"codons"..."13"
(SENT
  (S
    (NP-SBJ-3
      (NP (NNS:[705..714] Mutations))
      (PP (IN:[715..721] within)
        (NP (DT:[722..725] the)
          (NML
            (NML (NN:[726..729] p53)
              (PRN (-LRB-:[730..731] -LRB-)
                (NP
                  (NP
                    (NML-4 (NNS:[731..736] exons))
                    (CD:[737..738] 5))
                  (PP (HYPH:[738..739] -)
                    (NP
                      (NML-4 (-NONE-:[739..739] *P*))
                      (CD:[739..740] 8))))
                (-RRB-:[740..741] -RRB-))
              (NML-2 (-NONE-:[741..741] *P*)))
            (CC:[742..745] and)
            (NML (NN:[746..754] c-Ki-ras)
              (PRN (-LRB-:[755..756] -LRB-)
                (NP
                  (NP
                    (NML-1 (NNS:[756..762] codons))
                    (CD:[763..765] 12))
                  (CC:[766..769] and)
                  (NP
                    (NML-1 (-NONE-:[769..769] *P*))
                    (CD:[771..773] 13)))
                (-RRB-:[773..774] -RRB-))
              (NML-2 (NNS:[775..780] genes)))))))
    (VP (VBD:[781..785] were)
      (VP (VBN:[786..794] detected)
        (NP-3 (-NONE-:[794..794] *))
        (PP-MNR (IN:[795..797] by)
          (NP
            (NP (NN:[798..801] PCR)
              (NML (JJ:[802..808] single) (HYPH:[808..809] -)
                   (NN:[809..815] strand))
              (NN:[816..828] conformation) (NN:[829..841] polymorphism)
               (NN:[842..850] analysis))
            (VP (VBN:[852..860] followed)
              (NP-SBJ (-NONE-:[860..860] *))
              (PP (IN:[861..863] by)
                (NP-LGS (NN:[864..874] sequencing))))))))
    (.:[874..875] .)))

;sentence 8 Span:876..963
;A high correlation was observed between the MIB-1 LI and  SPF value
;(rho=0.81; P<0.01).
;[920..925]:gene-protein:"MIB-1"
(SENT
  (S
    (NP-SBJ-1 (DT:[876..877] A) (JJ:[878..882] high) (NN:[883..894] correlation))
    (VP (VBD:[895..898] was)
      (VP (VBN:[899..907] observed)
        (NP-1 (-NONE-:[907..907] *))
        (PP (IN:[908..915] between)
          (NP
            (NP (DT:[916..919] the) (NN:[920..925] MIB-1) (NN:[926..928] LI))
            (CC:[929..932] and)
            (NP (NN:[934..937] SPF) (NN:[938..943] value))))
        (PRN (-LRB-:[944..945] -LRB-)
          (S
            (S
              (NP-SBJ (SYM:[945..948] rho))
              (VP (SYM:[948..949] =)
                (NP (CD:[949..953] 0.81))))
            (::[953..954] ;)
            (S
              (NP-SBJ (NN:[955..956] P))
              (VP (SYM:[956..957] <)
                (NP (CD:[957..961] 0.01)))))
          (-RRB-:[961..962] -RRB-))))
    (.:[962..963] .)))

;sentence 9 Span:964..1049
;Moreover, p53 gene mutations were associated with  either high MIB-1 LI and
;high SPF.
;[974..977]:gene-rna:"p53"
;[1027..1032]:gene-protein:"MIB-1"
(SENT
  (S
    (ADVP (RB:[964..972] Moreover))
    (,:[972..973] ,)
    (NP-SBJ-1 (NN:[974..977] p53) (NN:[978..982] gene)
              (NNS:[983..992] mutations))
    (VP (VBD:[993..997] were)
      (VP (VBN:[998..1008] associated)
        (NP-1 (-NONE-:[1008..1008] *))
        (PP-CLR (IN:[1009..1013] with)
          (NP (DT:[1015..1021] either)
            (NP (JJ:[1022..1026] high) (NN:[1027..1032] MIB-1)
                (NN:[1033..1035] LI))
            (CC:[1036..1039] and)
            (NP (JJ:[1040..1044] high) (NN:[1045..1048] SPF))))))
    (.:[1048..1049] .)))

;sentence 10 Span:1050..1126
;In univariate analysis, SPF and MIB-1 levels  were related to risk of death.
;[1082..1087]:gene-protein:"MIB-1"
(SENT
  (S
    (PP (IN:[1050..1052] In)
      (NP (JJ:[1053..1063] univariate) (NN:[1064..1072] analysis)))
    (,:[1072..1073] ,)
    (NP-SBJ-2
      (NP (NN:[1074..1077] SPF)
        (NML-1 (-NONE-:[1077..1077] *P*)))
      (CC:[1078..1081] and)
      (NP (NN:[1082..1087] MIB-1)
        (NML-1 (NNS:[1088..1094] levels))))
    (VP (VBD:[1096..1100] were)
      (VP (VBN:[1101..1108] related)
        (NP-2 (-NONE-:[1108..1108] *))
        (PP-CLR (TO:[1109..1111] to)
          (NP
            (NP (NN:[1112..1116] risk))
            (PP (IN:[1117..1119] of)
              (NP (NN:[1120..1125] death)))))))
    (.:[1125..1126] .)))

;sentence 11 Span:1127..1387
;The association between overall survival and  DNA-ploidy or p53 mutations did
;not reach statistical significance, but a  slightly better survival was
;observed for patients either with DNA-diploid  tumours or without mutations
;(P=0.05 and P=0.06, respectively).
;[1187..1190]:gene-rna:"p53"
;[1311..1322]:variation-type:"DNA-diploid"
;[1324..1331]:malignancy:"tumours"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[1127..1130] The) (NN:[1131..1142] association))
        (PP (IN:[1143..1150] between)
          (NP
            (NP (JJ:[1151..1158] overall) (NN:[1159..1167] survival))
            (CC:[1168..1171] and)
            (NP
              (NP (NN:[1173..1176] DNA) (HYPH:[1176..1177] -)
                  (NN:[1177..1183] ploidy))
              (CC:[1184..1186] or)
              (NP (NN:[1187..1190] p53) (NNS:[1191..1200] mutations))))))
      (VP (VBD:[1201..1204] did) (RB:[1205..1208] not)
        (VP (VB:[1209..1214] reach)
          (NP (JJ:[1215..1226] statistical) (NN:[1227..1239] significance)))))
    (,:[1239..1240] ,) (CC:[1241..1244] but)
    (S
      (NP-SBJ-1 (DT:[1245..1246] a)
        (ADJP (RB:[1248..1256] slightly) (JJR:[1257..1263] better))
        (NN:[1264..1272] survival))
      (VP (VBD:[1273..1276] was)
        (VP (VBN:[1277..1285] observed)
          (NP-1 (-NONE-:[1285..1285] *))
          (PP (IN:[1286..1289] for)
            (NP
              (NP (NNS:[1290..1298] patients))
              (PP (CC:[1299..1305] either)
                (PP (IN:[1306..1310] with)
                  (NP
                    (ADJP (NN:[1311..1314] DNA) (HYPH:[1314..1315] -)
                          (JJ:[1315..1322] diploid))
                    (NNS:[1324..1331] tumours)))
                (CC:[1332..1334] or)
                (PP (IN:[1335..1342] without)
                  (NP (NNS:[1343..1352] mutations))))))
          (PRN (-LRB-:[1353..1354] -LRB-)
            (FRAG
              (S
                (NP-SBJ (NN:[1354..1355] P))
                (VP (SYM:[1355..1356] =)
                  (NP (CD:[1356..1360] 0.05))))
              (CC:[1361..1364] and)
              (S
                (NP-SBJ (NN:[1365..1366] P))
                (VP (SYM:[1366..1367] =)
                  (NP (CD:[1367..1371] 0.06))))
              (,:[1371..1372] ,)
              (ADVP (RB:[1373..1385] respectively)))
            (-RRB-:[1385..1386] -RRB-)))))
    (.:[1386..1387] .)))

;sentence 12 Span:1388..1549
;SPF was shown by  multivariate Cox model analysis to be an independent
;prognostic variable and  thus it might be a useful prognostic factor in
;patients with CLM.
;[1545..1548]:malignancy:"CLM"
(SENT
  (S
    (S
      (NP-SBJ-1 (NN:[1388..1391] SPF))
      (VP (VBD:[1392..1395] was)
        (VP (VBN:[1396..1401] shown)
          (PP-MNR (IN:[1402..1404] by)
            (NP (JJ:[1406..1418] multivariate) (NNP:[1419..1422] Cox)
                (NN:[1423..1428] model) (NN:[1429..1437] analysis)))
          (S
            (NP-SBJ-1 (-NONE-:[1437..1437] *))
            (VP (TO:[1438..1440] to)
              (VP (VB:[1441..1443] be)
                (NP-PRD (DT:[1444..1446] an) (JJ:[1447..1458] independent)
                        (JJ:[1459..1469] prognostic) (NN:[1470..1478] variable))))))))
    (CC:[1479..1482] and)
    (S
      (ADVP (RB:[1484..1488] thus))
      (NP-SBJ (PRP:[1489..1491] it))
      (VP (MD:[1492..1497] might)
        (VP (VB:[1498..1500] be)
          (NP-PRD
            (NP (DT:[1501..1502] a) (JJ:[1503..1509] useful)
                (JJ:[1510..1520] prognostic) (NN:[1521..1527] factor))
            (PP (IN:[1528..1530] in)
              (NP
                (NP (NNS:[1531..1539] patients))
                (PP (IN:[1540..1544] with)
                  (NP (NN:[1545..1548] CLM)))))))))
    (.:[1548..1549] .)))

;section 13 Span:1553..1597
;PMID: 9853427 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1553..1557] PMID) (::[1557..1558] :) (CD:[1559..1566] 9853427)
        (IN:[1567..1568] -LSB-) (NNP:[1568..1574] PubMed) (HYPH:[1575..1576] -)
        (JJ:[1577..1584] indexed) (IN:[1585..1588] for)
        (NNP:[1589..1597] MEDLINE-RSB-)))
